Traditional Chinese medicine as an adjunctive therapy improves cardiac function and reduces serum inflammatory markers in patients with chronic heart failure.

IF 1.5 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2025-06-13 DOI:10.5937/jomb0-54440

Yonghong Zheng, Chunhui Huang, Wei Zhang, Yiping Shi, Fangchao Chen, Jianru Zhou

{"title":"Traditional Chinese medicine as an adjunctive therapy improves cardiac function and reduces serum inflammatory markers in patients with chronic heart failure.","authors":"Yonghong Zheng, Chunhui Huang, Wei Zhang, Yiping Shi, Fangchao Chen, Jianru Zhou","doi":"10.5937/jomb0-54440","DOIUrl":null,"url":null,"abstract":"Background: To evaluate the impact of traditional Chinese medicine treatment versus standard treatment on cardiac function metrics, serum inflammatory markers, and quality of life in patients with chronic heart failure (CHF).Methods: A total of 40 CHF patients were randomly assigned to either the observation group (TCM treatment) or the control group (standard Western therapy), with 20 patients in each group. Over a 3-month treatment period, primary outcomes including cardiac function indicators (ejection fraction [EF], cardiac output [CO], left ventricular end-diastolic pressure [LVEDP]), exercise tolerance (6-minute walk test [6MWT] results), and inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-a]) were assessed. Secondary outcomes included the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores and adverse reaction rates. Statistical analysis was performed using t-tests and chi-square tests, with significance set at P < 0.05.Results: After treatment, the observation group showed significantly greater improvements in EF (44.14% ± 4.95% vs. 40.15% ± 4.77%, P = 0.013), CO (4.62 ± 0.76 L/min vs. 4.10 ± 0.72 L/min, P = 0.032), LVEDP (18.76 ± 2.50 mmHg vs. 20.80 ± 2.64 mmHg, P = 0.016), and 6MWT results (526.84 ± 49.20 m vs. 432.75 ± 37.26 m, P < 0.001), compared to the control group. Inflammatory markers and MLHFQ scores were also significantly improved, while the adverse reaction rate was lower in the observation group (0.00% vs. 20.00%, P = 0.035).Conclusions: TCM as an adjunctive therapy demonstrates superior efficacy and safety compared to standard treatment for CHF, with significant improvements in cardiac function, exercise tolerance, and inflammatory markers. These findings provide quantitative evidence supporting the clinical application of TCM in CHF management.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"507-514"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357615/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-54440","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To evaluate the impact of traditional Chinese medicine treatment versus standard treatment on cardiac function metrics, serum inflammatory markers, and quality of life in patients with chronic heart failure (CHF).

Methods: A total of 40 CHF patients were randomly assigned to either the observation group (TCM treatment) or the control group (standard Western therapy), with 20 patients in each group. Over a 3-month treatment period, primary outcomes including cardiac function indicators (ejection fraction [EF], cardiac output [CO], left ventricular end-diastolic pressure [LVEDP]), exercise tolerance (6-minute walk test [6MWT] results), and inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-a]) were assessed. Secondary outcomes included the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores and adverse reaction rates. Statistical analysis was performed using t-tests and chi-square tests, with significance set at P < 0.05.

Results: After treatment, the observation group showed significantly greater improvements in EF (44.14% ± 4.95% vs. 40.15% ± 4.77%, P = 0.013), CO (4.62 ± 0.76 L/min vs. 4.10 ± 0.72 L/min, P = 0.032), LVEDP (18.76 ± 2.50 mmHg vs. 20.80 ± 2.64 mmHg, P = 0.016), and 6MWT results (526.84 ± 49.20 m vs. 432.75 ± 37.26 m, P < 0.001), compared to the control group. Inflammatory markers and MLHFQ scores were also significantly improved, while the adverse reaction rate was lower in the observation group (0.00% vs. 20.00%, P = 0.035).

Conclusions: TCM as an adjunctive therapy demonstrates superior efficacy and safety compared to standard treatment for CHF, with significant improvements in cardiac function, exercise tolerance, and inflammatory markers. These findings provide quantitative evidence supporting the clinical application of TCM in CHF management.

查看原文本刊更多论文

中药作为辅助治疗可改善慢性心力衰竭患者的心功能，降低血清炎症标志物。

背景：评价中药治疗与标准治疗对慢性心力衰竭（CHF）患者心功能指标、血清炎症标志物和生活质量的影响。方法：将40例CHF患者随机分为观察组（中医治疗）和对照组（西医标准治疗），每组20例。在3个月的治疗期间，主要结局包括心功能指标（射血分数[EF]、心输出量[CO]、左室舒张末压[LVEDP]）、运动耐量（6分钟步行试验[6MWT]结果）和炎症标志物（高敏c -反应蛋白[hs-CRP]、白细胞介素-6 [IL-6]、肿瘤坏死因子- α [TNF-a]）的评估。次要结局包括明尼苏达州心衰生活问卷（MLHFQ）评分和不良反应率。采用t检验和卡方检验进行统计学分析，P < 0.05为显著性。结果：治疗后，观察组患者EF（44.14%±4.95%比40.15%±4.77%,P = 0.013）、CO（4.62±0.76 L/min比4.10±0.72 L/min, P = 0.032）、LVEDP（18.76±2.50 mmHg比20.80±2.64 mmHg, P = 0.016）、6MWT（526.84±49.20 m比432.75±37.26 m, P < 0.001）均较对照组显著改善。观察组患者炎症指标及MLHFQ评分均明显改善，不良反应发生率较对照组低（0.00% vs. 20.00%, P = 0.035）。结论：与标准治疗相比，中药辅助治疗CHF的疗效和安全性均优于标准治疗，心功能、运动耐量和炎症指标均有显著改善。这些结果为中医在慢性心力衰竭治疗中的临床应用提供了定量证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.